Technical Research on Equities: Ariad Pharma, MannKind, Galena Biopharma, and Novavax Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, December 23, 2013 LONDON, December 23, 2013 /PRNewswire/ -- On Friday, December 20, 2013, the U.S. equity market finished the week on a positive note. The S&P 500 ended the day at 1,818.32, up 0.48%; the Dow Jones Industrial Average closed at 16,221.14, up 0.26%; and the NASDAQ Composite Index finished at 4,104.74, up 1.15%. The S&P 500 Health Care Sector Index edged 0.45% higher to close the session at 635.97; and the S&P 500 Biotechnology Industry Index rose 1.62% to finish at 2,789.68. The S&P 500 Biotechnology Industry Index has gained 4.87% in the previous three trading sessions and 10.11% in the last three months, outperforming the S&P 500, which has gained 2.10% and 6.84% during the respective periods. The major movers in the health care sector included Ariad Pharmaceuticals Inc.(NASDAQ: ARIA),MannKind Corp.(NASDAQ: MNKD),Galena Biopharma Inc.(NASDAQ: GALE), and Novavax Inc. (NASDAQ: NVAX). All these companies are tracked by AAAResearchReports.com. Free technical research on ARIA, MNKD, GALE, and NVAX can be downloaded upon signing up at: http://www.aaaresearchreports.com/register/ Ariad Pharmaceuticals Inc.'s stock rallied on Friday, tracking gains in the broader market. The company's shares ended the day 16.49% higher at $6.43, after fluctuating between $5.67 and $7.75 during the trading session. A total of 150.02 million shares were traded, which is above the daily average volume of 22.94 million. The company's shares have rallied 54.57% in the previous three trading sessions and 70.11% in the last one month, outperforming the S&P 500, which has gained 2.10% and 0.75% during the respective periods. Additionally, Ariad Pharmaceuticals Inc.'s stock is trading above its 50-day moving average of $3.66. Sign up and read the complimentary report on ARIA at: http://www.AAAResearchReports.com/ARIA122313.pdf On Friday, MannKind Corp.'s stock finishsed the day at $5.01, up 1.62% from the previous day's closing price of $4.93. The company's shares vacillated between $4.94 and $5.05 during the trading session. A total of 7.57 million shares were traded, which is above the daily average volume of 4.72 million. The company's shares have advanced 1.44% in the previous three trading sessions, underperforming the S&P 500, which has gained 2.10% during the same period. Further, MannKind Corp.'s stock is trading below its 50-day and 200-day moving averages of $5.04 and $5.54, respectively. The free report on MNKD can be downloaded by signing up now at: http://www.AAAResearchReports.com/MNKD122313.pdf Shares in Galena Biopharma Inc. closed the day at$4.03, down 0.74%, after oscillating between$3.98 and$4.20 during Friday's trading session. A total of 10.99 million shares were traded, which is above the daily average volume of 4.54 million. Despite Friday's decline, the company's shares have rallied 102.51% in the previous three months, outperforming the S&P 500, which has gained 6.84% during the same period. Moreover, Galena Biopharma Inc.'s stock is trading above its 50-day and 200-day moving averages of $3.12 and $2.41, respectively. A free report on GALE can be accessed by registering at: http://www.AAAResearchReports.com/GALE122313.pdf Novavax Inc.'s stock rallied on Friday, hitting a new 52-week high of $4.97. The company's shares ended the day 5.34% higher at $4.93, after trading between $4.62 and $4.97 during the session. A total of 15.49 million shares were traded, which is above the daily average volume of 4.03 million. The company's shares have rallied 58.01% in the previous three months and 42.07% in the last one month, compared to a gain of 6.84% and 0.75% in the S&P 500 during the respective periods. Furthermore, Novavax Inc.'s stock is trading above its 50-day and 200-day moving averages of $3.40 and $2.72, respectively. Register with AAA Research Reports and download research on NVAX for free at: http://www.AAAResearchReports.com/NVAX122313.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: email@example.com
Technical Research on Equities: Ariad Pharma, MannKind, Galena Biopharma, and Novavax
Press spacebar to pause and continue. Press esc to stop.